Asset Details
Do you wish to reserve the book?
Autoimmune Lymphoproliferative Syndrome: An Overview
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Autoimmune Lymphoproliferative Syndrome: An Overview
Do you wish to request the book?
Autoimmune Lymphoproliferative Syndrome: An Overview
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Autoimmune Lymphoproliferative Syndrome: An Overview
2020
Overview
Autoimmune lymphoproliferative syndrome (ALPS) is an inherited nonmalignant lymphoproliferative disorder characterized by heterozygous mutations within the first apoptosis signal receptor (FAS) signaling pathway. Defects in FAS-mediated apoptosis cause an expansion and accumulation of autoreactive CD4− and CD8− (double-negative) T cells, leading to cytopenias, splenomegaly, lymphadenopathy, autoimmune disorders, and a greatly increased lifetime risk of lymphoma. The differential diagnosis of ALPS includes infection, other inherited immunodeficiency disorders, primary and secondary autoimmune syndromes, and lymphoma. The most consistent pathologic feature is a florid paracortical expansion of double-negative T cells in lymph nodes. A presumptive clinical diagnosis can be made from symptoms and a constellation of laboratory test results. However, a definitive diagnosis requires ancillary testing and enables disease subclassification. Recognition of ALPS is critical, as treatment with immunosuppressive therapies can effectively reduce or ameliorate symptoms for most patients.
Publisher
College of American Pathologists
Subject
/ Antigens
/ Autoimmune Lymphoproliferative Syndrome - diagnosis
/ Autoimmune Lymphoproliferative Syndrome - metabolism
/ Autoimmune Lymphoproliferative Syndrome - pathology
/ B cells
/ Genes
/ Humans
/ Kidneys
/ Lymphoma
/ Mutation
/ Patients
/ Signal Transduction - physiology
/ Sinuses
/ Systemic lupus erythematosus
/ T cells
/ Thyroid
